Roland Wilhelm Kolbeck - 02 Feb 2026 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Scientific Officer
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
02 Feb 2026
Net transactions value
$0
Form type
4
Filing time
06 Feb 2026, 18:06:23 UTC
Previous filing
05 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kolbeck Roland Wilhelm Chief Scientific Officer C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE /s/ Matthew Rothman, Attorney-in-Fact 06 Feb 2026 0002076327

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Award $0 +95,700 $0.000000 95,700 02 Feb 2026 Common Stock 95,700 Direct F1, F2
transaction ACRS Employee Stock Option (Right to Buy) Award $0 +334,900 $0.000000 334,900 02 Feb 2026 Common Stock 334,900 $3.61 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F3 Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.